Severe gastric ischemia after combined sclerotherapy for bleeding gastric ulcer

The choice of type of additional endoscopic therapy after epinephrine injection for bleeding peptic ulcers should be carefully individualized according to the characteristics of the ulcer. A 56-year-old man with diabetes mellitus was admitted with a 24-hour history of hematemesis and melena. On physical examination, his blood arterial pressure was 100/60 mmHg and heart rate 120/min. The hemoglobin level was 10.8 g/dL. Endoscopy showed fresh blood in the stomach and a 12-mm ulcer in the antrum with active oozing bleeding from a flat visible vessel (Forrest Ib classification). Injection of 8 mL of epinephrine (1/10 000 solution) on the edges of the ulcer did not stop bleeding (Fig. 1). Consequently, sclerotherapy with ethanolamine oleate (EO) was carried out and, immediately after injection of 1.5 mL a purplish protruding lesion appeared besides the ulcer (Fig. 2), which prevented the endoscopist from further administering EO. Hemostasis was successfully achieved after combined sclerotherapy (Fig. 3). After 48 h, the patient experienced abdominal pain and severe re-bleeding. Endoscopy revealed a deep ulcer covering half of the surface of the distal antrum (Fig. 4). Emergency vascular computed tomography ruled out arterial thrombosis. The patient was discharged after proton pump inhibitor perfusion and wide spectrum antibiotherapy for 1 week. A follow-up endoscopy 3 months later showed full resolution of the lesion.

Several case reports in the early 1990s highlighted the risk of extensive gastrointestinal necrosis following sclerosant plus epinephrine injection for bleeding ulcers [1–4]. Interestingly, spleen infarction has been recently reported following high-volume epinephrine injection in a gastric bleeding vessel, without sclerosants [5]. Inadvertent intra-arterial injection may result in either spasm or thrombosis leading to subsequent tissue ischemia or necrosis. Endoscopists should be aware of this rare complication. Lower volumes of sclerotherapy, lower speed of injection, avoiding the visible vessel and using alternative endoscopic therapies (clips, argon plasma coagulation) may minimize its occurrence.

Endoscopy_UCTN_Code_CCL_1AZ_2AC

Competing interests: None

J. Molina-Infante1, M. Fernandez-Bermúdez1, G. Vinagre-Rodríguez1
Department of Gastroenterology, Hospital San Pedro de Alcantara, Caceres, Spain

References

Bibliography
Endoscopy 2011; 43: E191
© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author
Dr. J. Molina-Infante
Unit of Gastroenterology
Hospital San Pedro de Alcantara
Pablo Naranjo s/n 10003
Caceres
Spain
xavi_molina@hotmail.com